Elsevier

Gynecologic Oncology

Volume 30, Issue 2, June 1988, Pages 265-273
Gynecologic Oncology

Regular article
CA 15-3 as a tumor marker in gynecological malignancies

https://doi.org/10.1016/0090-8258(88)90032-7Get rights and content

Abstract

Serum levels of CA 15-3 were measured in 778 samples from 270 patients with benign and malignant gynecological conditions. Malignant tumors were present in 180 patients including 58 cases with cancer of the ovary, 47 of the endometrium, 61 of the cervix, and 14 of the vulva. The 90 cases with benign conditions included 24 patients with ovarian tumors, 28 with fibromyomatosis, 18 with endometriosis, and 20 with endometrial hyperplasia. Of 180 cancer patients, CA 15-3 serum levels were elevated (>30 U/ml) in 74 cases (41%) and the frequency of abnormal marker values increased with clinical stage. Of 90 patients with benign conditions, high CA 15-3 levels were found in 5 cases (6%) with benign ovarian tumors. Elevated levels of the marker were most commonly seen in ovarian cancer patients (71%). In endometrial, cervical, and vulvar cancer abnormal CA 15-3 values occurred in 32, 26, and 14%, respectively. In endometrial cancer the percentage of positive marker levels increased with more infiltrating and/or less differentiated tumors. A positive correlation was found between residual tumor after surgery and CA 15-3 levels. Serial measurements in sera of patients who underwent chemotherapy showed a good correlation with response to treatment. CA 15-3 values were correlated with clinical course of disease in 87% of cases.

References (21)

There are more references available in the full text version of this article.

Cited by (45)

  • Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial

    2019, American Journal of Obstetrics and Gynecology
    Citation Excerpt :

    CA125 and CA 15-3 have been evaluated as potential screening biomarkers for endometrial cancer. CA 15-3 levels, however, are found to be elevated in only 36% of endometrial cancer patients, and CA125 has been shown to be elevated in 19–40% of endometrial cancer patients.27,28 Moreover, increased levels of CA125 may also be related to inflammatory conditions not related to endometrial cancer.

  • Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer

    2007, Gynecologic Oncology
    Citation Excerpt :

    Serum tumor markers, such as CA125 and CA15-3, have previously been evaluated as potential detection and prognostic indicators both for epithelial ovarian cancer and endometrial cancer. CA15-3 levels were found to be elevated in only 36% of endometrial cancer patients [13]. CA125 has been reported to be elevated in 19% to 40% of endometrial cancer patients [14–16].

View all citing articles on Scopus
View full text